Here, we are going to share Natco Pharma Share Price Target 2025 to 2040 on the basis of its fundamental and technical analysis.
Natco Pharma, established in 1981, is headquartered in Hyderabad, India. With a strong portfolio of products and a strong presence in both domestic and international markets, Natco has consistently demonstrated its commitment to quality and innovation.
The company is renowned for its expertise in developing generic versions of complex drugs, especially in the oncology segment.
Natco Pharma Share Key Information
| Company Name | Natco Pharma Ltd |
| Headquarters | Hyderabad |
| Sectors | Pharmaceuticals & Drugs |
| Market Cap | ₹ 25,811.52 Cr. |
| No. of Shares | 17.91Cr. |
| Book Value | ₹347.75 |
| Dividend Yield | 0.64% |
| ROCE | 29.02% |
| ROE | 25.38% |
| Face Value | ₹2 |
| Sales Growth | 51.80% |
| Profit Growth | 105.09% |
Natco Pharma Business Sector
- Research and Development: Investing heavily in R&D to develop generic versions of high-cost drugs.
- Strategic Partnerships: Collaborating with global pharmaceutical companies to expand its product reach.
- Focus on Oncology: Specializing in oncology drugs, which form a significant part of its revenue.
- International Expansion: Targeting international markets to increase its global footprint.
Board Members
- Sri V. C. Nannapaneni – Managing Director
- Sri A. D. M. Chavali – Executive Director
- Sri Rajeev Nannapaneni – Executive Director
- Sri D. Vijaya Bhaskar – Non-Executive Director
- Dr. Leela Digumarti – Independent Director
- Sri Lakshminarayana – Independent Director
Natco Pharma Share Quarterly Results
| PARTICULARS | Mar 2024 | Jun 2024 |
|---|---|---|
| Net Sales | 964.80 | 1,236.90 |
| Total Expenditure | 512.10 | 473.90 |
| Operating Profit | 452.70 | 763 |
| Other Income | 35.90 | 39.80 |
| Interest | 4.50 | 4.40 |
| Depreciation | 51.60 | 40.40 |
| Exceptional Items | 0 | 0 |
| Profit Before Tax | 432.50 | 758 |
| Tax | 83.40 | 121.70 |
| Profit After Tax | 349.10 | 636.30 |
| Adjusted EPS (Rs) | 19.50 | 35.55 |
Natco Pharma Company Profits and Losses
| PARTICULARS | Mar 2023 | Mar 2024 |
|---|---|---|
| Net Sales | 2,351 | 3,568.90 |
| Total Expenditure | 1,530.20 | 1,931.90 |
| Operating Profit | 820.80 | 1,637 |
| Other Income | 109.40 | 104.70 |
| Interest | 8.60 | 14.50 |
| Depreciation | 150.90 | 171.90 |
| Exceptional Items | 0 | 0 |
| Profit Before Tax | 770.70 | 1,555.30 |
| Tax | 133.60 | 248.70 |
| Net Profit | 637.10 | 1,306.60 |
| Adjusted EPS (Rs.) | 34.91 | 72.99 |
Natco Pharma Share Price Target 2025-2040
| Year | Initial Target | Year-End Target |
|---|---|---|
| 2025 | ₹1588 | ₹1689 |
| 2026 | ₹1695 | ₹1811 |
| 2027 | ₹1826 | ₹1952 |
| 2028 | ₹1965 | ₹2082 |
| 2029 | ₹2091 | ₹2247 |
| 2030 | ₹2265 | ₹2405 |
| 2035 | ₹3125 | ₹3450 |
| 2040 | ₹4210 | ₹4650 |
Natco Pharma Share Price Target 2025
| Year/Month | Predicted Target |
|---|---|
| January 2025 | ₹1588 |
| February 2025 | ₹1895 |
| March 2025 | ₹1602 |
| April 2025 | ₹1621 |
| May 2025 | ₹1611 |
| June 2025 | ₹1626 |
| July 2025 | ₹1643 |
| August 2025 | ₹1638 |
| September 2025 | ₹1656 |
| October 2025 | ₹1661 |
| November 2025 | ₹1677 |
| December 2025 | ₹1689 |
Natco Pharma Share Price Target 2026
| Year/Month | Predicted Target |
|---|---|
| January 2026 | ₹1695 |
| February 2026 | ₹1705 |
| March 2026 | ₹1721 |
| April 2026 | ₹1745 |
| May 2026 | ₹1765 |
| June 2026 | ₹1743 |
| July 2026 | ₹1762 |
| August 2026 | ₹1777 |
| September 2026 | ₹1786 |
| October 2026 | ₹1802 |
| November 2026 | ₹1795 |
| December 2026 | ₹1811 |
Natco Pharma Share Price Target 2027
| Year/Month | Predicted Target |
|---|---|
| January 2027 | ₹1826 |
| February 2027 | ₹1836 |
| March 2027 | ₹1849 |
| April 2027 | ₹1865 |
| May 2027 | ₹1877 |
| June 2027 | ₹1886 |
| July 2027 | ₹1870 |
| August 2027 | ₹1891 |
| September 2027 | ₹1905 |
| October 2027 | ₹1925 |
| November 2027 | ₹1938 |
| December 2027 | ₹1952 |
Natco Pharma Share Price Target 2028
| Year/Month | Predicted Target |
|---|---|
| January 2028 | ₹1965 |
| February 2028 | ₹1978 |
| March 2028 | ₹1989 |
| April 2028 | ₹2012 |
| May 2028 | ₹1998 |
| June 2028 | ₹2011 |
| July 2028 | ₹2026 |
| August 2028 | ₹2040 |
| September 2028 | ₹2051 |
| October 2028 | ₹2063 |
| November 2028 | ₹2077 |
| December 2028 | ₹2082 |
Natco Pharma Share Price Target 2029
| Year/Month | Predicted Target |
|---|---|
| January 2029 | ₹2091 |
| February 2029 | ₹2096 |
| March 2029 | ₹2102 |
| April 2029 | ₹2135 |
| May 2029 | ₹2165 |
| June 2029 | ₹2175 |
| July 2029 | ₹2184 |
| August 2029 | ₹2177 |
| September 2029 | ₹2193 |
| October 2029 | ₹2205 |
| November 2029 | ₹2227 |
| December 2029 | ₹2247 |
Natco Pharma Share Price Target 2030
| Year/Month | Predicted Target |
|---|---|
| January 2030 | ₹2265 |
| February 2030 | ₹2279 |
| March 2030 | ₹2261 |
| April 2030 | ₹2289 |
| May 2030 | ₹2301 |
| June 2030 | ₹2325 |
| July 2030 | ₹2349 |
| August 2030 | ₹2368 |
| September 2030 | ₹2358 |
| October 2030 | ₹2387 |
| November 2030 | ₹2398 |
| December 2030 | ₹2405 |
Natco Pharma Share Price Target 2035
| Year/Month | Predicted Target |
|---|---|
| January 2035 | ₹3125 |
| April 2035 | ₹3240 |
| July 2035 | ₹3310 |
| October 2035 | ₹3370 |
| December 2035 | ₹3450 |
Natco Pharma Share Price Target 2040
| Year/Month | Predicted Target |
|---|---|
| January 2040 | ₹4210 |
| April 2040 | ₹4250 |
| July 2040 | ₹4350 |
| October 2040 | ₹4490 |
| December 2040 | ₹4650 |
Natco Pharma Shareholding Pattern
| Terms | Percentage |
|---|---|
| Promoters | 49.71% |
| FIIs | 17.45% |
| DIIs | 7.86% |
| Others | 0% |
| Public | 24.97% |
Natco Pharma Company Competitors
Bull Case of Natco Pharma (Reasons to Invest)
- Strong Product Pipeline: Natco’s focus on developing complex generics provides a competitive edge.
- Market Leader in Oncology: Its leadership in the oncology segment offers significant growth opportunities.
- Global Expansion: Strategic international partnerships are likely to enhance revenue streams.
Bear Case of Natco Pharma (Risks Involved)
- Regulatory Challenges: Potential delays due to stringent regulatory environments can impact product launches.
- Competitive Pressure: Intense competition in the generics market could affect profit margins.
- Dependence on Key Products: Over-reliance on a few blockbuster drugs may pose risks if market dynamics change.
Natco Pharma Share Price Target: FAQ
What will be the target of Natco Pharma Share for the year 2025?
By the end of the year 2025, its share price can reach ₹1689.
What will be the target of Natco Pharma Share for the year 2026?
By the end of the year 2026, its share price can reach ₹1811.
What will be the target of Natco Pharma Share for the year 2027?
By the end of the year 2027, its share price can reach ₹1952.
What will be the target of Natco Pharma Share for the year 2028?
By the end of the year 2028, its share price can reach ₹2082.
What will be the target of Natco Pharma Share for the year 2029?
By the end of the year 2029, its share price can reach ₹2247.
What will be the target of Natco Pharma Share for the year 2030?
By the end of the year 2030 its share price can reach ₹2405.
What is the Current market cap of Natco Pharma company?
At present the market cap of this company is ₹ 25,811.52 Cr.
What is the NSE symbol of Natco Pharma company?
The symbol of this company in NSE exchange is NATCOPHARM.
What is the BSE symbol of Natco Pharma company?
The symbol of this company in BSE exchange is 524816.
Read Also:
Reliance Power Share Price Target 2025 to 2040 Forecast & Fundamentals
TAAL Enterprises Share Price Target 2025 to 2040 Forecast & Fundamentals
